ERBB2 and metastatic malignant neoplasm in the lymph nodes: Other clinical features, such as HR/HER2 status, nuclear or histological grade, stage, menupause method, primary treatment history, bone and lymph node metastasis were not significantly distinct among Fulvestrant early users and late users.